Tenon Medical, Inc. (TNON)

Tenon Medical addresses a customer pain point that has long been underserved in spine surgery. Millions of people live with chronic lower back pain caused by dysfunction or degeneration of the sacroiliac joint—the connection between the sacrum and the ilium at the base of the spine. Traditional spine surgery either treats problems higher up in the lumbar spine or addresses broader stability issues. For patients whose pain is specifically sacroiliac in origin, options have historically been limited. Tenon’s Catamaran system offers a focused, less invasive solution: a single titanium implant that stabilizes the SI joint, restoring alignment and reducing pain without the complexity of bigger spinal fusion operations.

What is the sacroiliac joint and why does it matter?

The sacroiliac joint connects the lower spine to the pelvis. It bears enormous load during sitting, standing, and movement, and it is capable of limited motion. When it becomes unstable—either from injury, degenerative wear, or structural abnormality—pain can be severe and persistent. Studies suggest that 15 to 30 percent of all chronic lower back pain originates in the SI joint rather than higher in the lumbar spine. For decades, treatment options were either conservative (physical therapy, pain management) or excessive (traditional lumbar fusion surgery aimed at levels above the SI joint). There was no surgical solution focused specifically on the SI joint itself until the last 15 years, and even now, fewer options exist than in adjacent spine markets.

How does the Catamaran system work?

Tenon’s flagship product is the Catamaran SI Joint Fusion System, cleared by the FDA in 2022. The system uses a single titanium implant—shaped like a catamaran hull, hence the name—that is placed across the SI joint during a minimally invasive surgical procedure. One pontoon of the device is fixed into the ilium (the larger pelvic bone) and the other into the sacrum. The approach angle avoids critical nerves and blood vessels that run nearby. Once in place, the implant physically stabilizes the joint, preventing excess motion and reducing pain. The surgical access requires only a small incision, and recovery is faster than traditional open spine fusion.

The company has expanded the Catamaran family. The Catamaran SE variant, launched in 2024, offers a smaller, lower-profile implant for patients with smaller SI joint anatomy or for revision procedures on joints previously treated with other devices. This flexibility is valuable because SI joint anatomy varies substantially between individuals, and revision cases—patients who have had previous SI joint surgery—require different considerations than primary fusion.

What is the market, and who buys?

Chronic lower back pain is enormous and fragmented. The addressable market for SI joint fusion specifically includes patients with confirmed SI joint dysfunction who fail conservative care and are surgical candidates. This is a subset of the broader back-pain market, but it is not small: with tens of millions of Americans experiencing chronic lower back pain, and an estimated 15–30 percent of those related to the SI joint, the potential patient pool is in the millions. The customers are orthopedic surgeons and neurosurgeons who specialize in spine procedures. Tenon’s job is to convince surgeons that its implant is better—easier to use, better outcomes, better revision profile—than competing SI joint fusion systems (other implant makers offer similar products).

Tenon’s revenue stream is straightforward: the company sells implants and surgical kits to hospitals and surgical centers where the procedures take place. The company does not perform the surgery itself; surgeons do. But Tenon maintains relationships with key surgeons and surgical programs, manages training on the technique, handles the supply chain, and pursues reimbursement approval with insurance companies. A single implant procedure might generate several thousand dollars in revenue to Tenon, depending on the reimbursement rate and the negotiated hospital price.

What makes Tenon distinctive?

Tenon is a young company—founded in 2012, it took a decade to achieve FDA clearance and then scale the commercial operation. The Catamaran system is not the only SI joint fusion implant on the market; competitors like Si-Bone and others have been in the market longer. However, Tenon differentiated itself through the simplicity of the single-implant design (competitors sometimes use two implants) and the surgical approach, which some surgeons find easier to execute and less risky than alternative techniques.

The company’s strategy since launch has been to broaden its platform. In 2024, Tenon acquired two companies—SiVantage and SIMPL Medical—that brought additional SI joint fusion technologies and broader sacropelvic expertise into the fold. This transforms Tenon from a single-product company to a portfolio player with multiple implant options and a deeper product pipeline. The goal is to offer surgeons a broader range of solutions and to build a sacropelvic fusion franchise that extends beyond just the SI joint into adjacent problems (like lumbosacral instability).

What are the risks and competitive pressures?

The SI joint fusion market is growing but remains much smaller than the broader spine-surgery market. This means adoption requires consistent marketing and surgeon education. Tenon is smaller and less established than some larger spine-device companies, so it has fewer resources to support surgeon training and hospital relationships. Surgical adoption is competitive and can be slow.

Reimbursement is another key risk. Insurance companies determine what they will pay for SI joint fusion, and this varies by plan and geography. Poor reimbursement rates or insurance rejections can eliminate a case’s profitability for the hospital and thus the surgeon’s willingness to use the device. Tenon works with hospitals and surgeons to navigate reimbursement, but this is always a risk in medical devices, particularly for newer indications.

Finally, product liability is an inherent risk in surgical implants. If implants fail, migrate, or cause complications, patients may sue, and the company faces recalls or regulatory action. Tenon mitigates this with rigorous quality control and postmarket surveillance, but the risk is never zero.

How should an investor research Tenon?

The company’s 10-K (SEC CIK 0001560293) details the current product portfolio, recent acquisitions, and a financial breakdown by product and segment. The earnings calls are where management discusses adoption trends, reimbursement updates, and pipeline products. Key metrics include the number of procedures performed (a leading indicator of surgeon adoption), the gross margin on device sales (which reflects hospital pricing power and manufacturing costs), and cash burn (the company is pre-profitability and depends on capital raises to fund R&D and commercial operations).

The strategic question is whether the acquisitions of SiVantage and SIMPL can be successfully integrated and whether the expanded product portfolio accelerates surgeon adoption and revenue growth. Another critical question is whether the company can reach profitability before it exhausts its capital, or whether it will need to raise more equity and dilute shareholders further. And the larger competitive question is whether the SI joint fusion market continues to grow and consolidate toward leaders, or whether the market remains fragmented with thin margins for smaller players.